国内胰腺癌药物经济学评价

Pharmacoeconomic evaluation of pancreatic cancer in China

目的:对国内胰腺癌的经济学评价研究进行综述,以期为后续研究提供参考。方法:计算机检索PubMed、Web of Science、Embase、Scopus、中国知网、万方、维普、中国生物医学文献数据库,搜集胰腺癌的药物经济学评价,检索时限为建库至2022年12月31日。利用Excel提取文献信息,使用CHEERS 2022评估文献质量。结果:初检共获得105篇文献,最终纳入13篇,文献质量整体良好,临床效果数据来源于11项随机对照试验。纳入文献均采用Markov模型,成本主要考虑直接成本,效用值来源于已有文献研究,敏感性分析多采用单因素敏感性分析和概率敏感性分析,在不同的疾病类型下,吉西他滨单药治疗或联合用药具有经济性的概率较大。结论:国内胰腺癌药物的经济学评价仍有较大研究空间,缺乏靶向药物以及真实世界研究的经济学评价。

OBJECTIVE To review the studies on the economic evaluation of pancreatic cancer in China,so as to provide a reference for subsequent research.METHODS PubMed,Web of Science,Embase,Scopus,CNKI,WanFang Data,VIP,and CBM databases were conducted to collect pharmacoeconomic evaluations of pancreatic cancer,with a search time frame from inception to December 31,2022.Literature information was extracted using Excel and the quality of the literature was assessed using CHEERS 2022.RESULTS A total of 105 papers were obtained in the initial review and 13 papers were finally included,with overall generally good quality literature and clinical outcome data from 11 randomized controlled trials.Markov models were used in the included literature,and costs were mainly considered as direct costs,utility values were derived from the existing literature research,sensitivity analysis mostly used single-factor sensitivity analysis and probabilistic sensitivity analysis.CONCLUSION Under different disease types,gemcitabine monotherapy or combination therapy has a greater probability of economy.The economic evaluation of domestic pancreatic cancer drugs still has more research space,and there is a lack of economic evaluation of targeted drugs and real-world research.